Neurizon Therapeutics Limited has released a press release.
Phase IIb Canine Trial Identifies Therapeutic Window for MPL
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust Receives $750k R&D Tax Incentive Refund
- Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
- Update on Phase IIb Clinical Trial of Monepantel in Pet Dogs
- Licensing Agreement to Develop Waste to Fuels Technology
- Update on Phase IIb Clinical Trial recruitment
Later from Neurizon Therapeutics
- PharmAust receives ethics approval for Phase I trial in MND
- Phase IIb Dog Trial Achieves Interim Clinical Endpoints
- PharmAust and WEHI to Investigate HTLV-1 Viral Infections
- Monepantel and monepantel sulfone COVID-19 anti-viral update
- Epichem Completes Build of OHD Benchtop Flow Reactor
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics